Clinical laboratory testing is one of the most important sectors of medical care. Although it is generally involved in over 70% of medical diagnoses, it accounts for less than 5% of overall healthcare expenditures. The term clinical laboratory testing usually refers to determining the concentration or activity of a protein, carbohydrate, lipid, electrolyte, enzyme or small molecule in easily collected body fluids such as blood, serum, plasma, urine and saliva. This TriMark Publications report describes the specific segments of the clinical laboratory testing business and the strategies used by laboratory companies to develop new business opportunities. The study presents emerging business practices and analyzes the partnerships and alliances that various key sector players have forged or could forge in the near future. New clinical laboratory business methods are also examined to identify lead positions and potential future growth areas. Moreover, the report profiles leading companies in the clinical laboratory industry, with a primary focus on companies that actively analyze and market laboratory data.
The author of this report is a Ph.D. in biochemistry from the University of Minnesota with mans decades of experience in scientific writing and as a medical industry analyst. He has been a senior director of se cml large regional and national healthcare laboratories. He has over 30 years of experience in laboratory testing and instrument and reagent development technology as a licensed clinical laboraton director, as well as extensive experience in senior level management positions in biotech and niedictil sen ice companies. The editor has a Ph.D. in medicinal chemistry from Medical College of Virginia, Virginia Commonwealth University, with postdoctoral work in clinical assay development and validation conibined with molecular biology, and has worked in small and large pharmaceutical companies in the department of drug safet e aluation to support eflbrts in drug discovery and for commercialization of new chemical entities as drugs for over 15 sears.
Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of infoimation include the non-governmental organi/ations (NGOs) such as the World Health Organization (WHO) and governmental entities like the U.S. Department of Hlealth and Human Services (HHS) and U.S. federal agencies such as the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention(CDC). Where possible and practicable, the most recent data available have been used.
Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy or completeness of any information or omission or for the results obtained by the use of such infonnation. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes.
TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that we publish annually. We extract relevant data and analytics from TriMark' s research as part of this data collection.
TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.
Browse more In Vitro Diagnostics Market Research Reports